Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NMEG-CGRP
- Development stage
- Preclinical
- Lead developer
- University of South Carolina
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
NMEG-CGRP is a peptoid-modified analog of alpha-calcitonin gene-related peptide (α-CGRP) developed by researchers at the University of South Carolina. It consists of human α-CGRP with two N-methoxyethylglycine (NMEG) peptoid units attached to the N-terminus. This modification is designed to enhance the peptide's bioavailability and stability by protecting it from enzymatic degradation, specifically by insulin-degrading enzyme (IDE). In preclinical studies involving a transverse aortic constriction (TAC) mouse model of pressure-overload heart failure, NMEG-CGRP demonstrated significant cardioprotective effects, including improved fractional shortening and reduced cardiac cell size, fibrosis, and apoptosis. It acts as a bioactive CGRP receptor agonist and vasodilator, positioning it as a potential therapeutic agent for heart failure.
- Other names
- N-methoxyethylglycine-CGRPpeptoid derivative of alpha-calcitonin gene related peptide
02
Targets
Calcitonin gene-related peptide type 1 receptor
Beyond the preview
Go deeper on NMEG-CGRP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NMEG-CGRP.